Skip to main content
|

Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis

Short Title: ASPIRE


Enrollment Status: Recruiting

NCT #: NCT06588686

Specialty Area: Pulmonology

Condition Studied: Idiopathic Pulmonary Fibrosis

Age Groups: Adult; Older Adult

Phase: II


Study Information

Summary / Purpose

To evaluate the efficacy of buloxibutid compared to placebo in participants with idiopathic pulmonary fibrosis as assessed by Forced Vital Capacity (FVC)

Study Type: Interventional
Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:
  • Adults 40+ years of age
  • Diagnosed with idiopathic pulmonary fibrosis within the last 7 years
  • No heart failure NYHA Class IV

What's Involved

Participation in the study will include:
  • Medication administered orally, twice a day

Principal Investigator

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

ER Wait Times

How are wait times calculated?

Our estimated ER wait times reflect the average time from check-in to being seen by a medical professional during triage, where patients are prioritized based on the severity of their condition.

Health & Wellness eNews
Sign Up